HarmoniaMentis
Resources
For materials designed to support healthcare professionals and their patients.
Welcome to HarmoniaMentis
This website is dedicated to providing UK and Ireland healthcare professionals with up-to-date information on the management of refractory focal epilepsy in adults.
Epilepsy impacts every aspect of life for patients and their loved ones. At Harmoniamentis.co.uk, Angelini Pharma have created a website that offers articles, videos and practical information to help healthcare professionals stay informed. The site also provides access to useful resources that support patients and carers.
Latest content
Discover ONTOZRY®▼ (cenobamate)
Efficacy
Tolerability Profile
Prescribers must understand the drug’s AE profile, contraindications, and key safety warnings to formulate an informed treatment plan. This page gives an overview of these for ONTOZRY.
Videos and Events
Explore expert-led discussions on key aspects of epilepsy management, featuring Professor John Paul Leach, Consultant Neurologist and Senior Clinical Fellow at Angelini Pharma.
Clinical Insights
Contact Us
Have a question or want to connect? Find all the ways to connect with Angelini Pharma on our contact page.
United Kingdom: ONTOZRY® (cenobamate) is indicated for the adjunctive treatment of focal–onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti–epileptic medicinal products.1
Republic of Ireland: ONTOZRY® (cenobamate) is indicated for the adjunctive treatment of focal–onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti–epileptic medicinal products.1
1. ONTOZRY® Summary of Product Characteristics. United Kingdom and European Union.
MAT-UKI-0491-P | August 2026
